TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02302144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance & Strengthening Exercises
Description: Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance & Strengthening Exercises
Description: Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
Study: NCT00685841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 50 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol MDI
Description: Salmeterol MDI 42 mcg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID MDI
Study: NCT04328922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbial transplantation
Description: Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsuls
Description: capsules of glycerol and saline (placebo).
Study: NCT03752463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-A group
Description: DAOI with A dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-B group
Description: DAOI with B dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-C group
Description: DAOI with C dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT04355663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor program activating therapy
Description: Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
Study: NCT04797923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Treatment: IP chemotherapy + Systemic chemotherapy
Description: 1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2. Response evaluation after 4 cycles of IP + systemic chemotherapy
Description: 2. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles.
Study: NCT04355663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta's reflex locomotion
Description: Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional electric stimulation
Description: Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
Study: NCT00986180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUCYNTA
Description: 50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: 5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
Study: NCT01130636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
Study: NCT02773459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162+capecitabine
Description: In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162+capecitabine
Description: In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
Study: NCT01580813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
Study: NCT04405895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Diet
Description: Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
Study: NCT00860119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam sublingual tablet
Description: 1 mg alprazolam sublingual tablet, given as a single dose to each subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam oral tablet
Description: 1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
Study: NCT03235817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Description: The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Description: The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study: NCT04405895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allday Diet
Description: Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
Study: NCT02195466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)
Description: 500 mg bid on days 7-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: 200 mg bid on days 7-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (FCZ)
Description: 200 mg loading dose on day 1, followed by 100 mg qd until day 13
Study: NCT03097835

Intervention type: DRUG
Group type: OTHER
Intervention: Hyper-Diluted Botox
Description: 0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle

Intervention type: DRUG
Group type: OTHER
Intervention: Hyper-Diluted Botox
Description: 0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle

Intervention type: DRUG
Group type: OTHER
Intervention: Topical anesthesia
Description: Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes

Intervention type: DRUG
Group type: OTHER
Intervention: Topical anesthesia
Description: Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% saline solution
Description: 0.1ml of 0.9% saline solution will be administered to the side of the face

Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% saline solution
Description: 0.1ml of 0.9% saline solution will be administered to the side of the face
Study: NCT01233921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00871663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT03001661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Description: DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
Study: NCT03438214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Continuous infusion
Description: Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Intermittent infusion
Description: Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
Study: NCT03421158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding
Description: Newborns were breastfed during the procedure
Study: NCT02877797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap
Description: cap assisted esophagogastroduodenoscopy
Study: NCT03421158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral sucrose
Description: Newborns were given oral sucrose during the procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact
Description: Newborns were placed in direct contact with their mothers during the procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Description: newborns were given a pacifier to suck on during the procedure
Study: NCT01483859

Intervention type: OTHER
Group type: OTHER
Intervention: preoperative liver stiffness measurement
Description: Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
Study: NCT03816215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer experience
Description: Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
Study: NCT03001661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
Study: NCT02372071

Intervention type: DEVICE
Group type: OTHER
Intervention: BiliCare
Description: Two measurements with the BiliCare device
Study: NCT04383236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure oral gel
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
Study: NCT01124344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 3 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 10 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 30 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 45 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 60 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 90 mg, Once Daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
Study: NCT02475941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Weight bearing
Description: The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Weight Bearing
Description: The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.
Study: NCT00000408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient education evaluation
Study: NCT01527617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry
Description: beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Cranberry beverage
Description: Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
Study: NCT02483832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
Study: NCT02005887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg orally every day for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg orally every day for 6 cycles
Study: NCT00074776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Participants will receive lamotrigine.
Study: NCT00760565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 3mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 3mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 7mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 7mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7mg/kg iv every 28 days for 3 infusions
Study: NCT03674671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
Study: NCT00760565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20mg/kg iv every 28 days for 3 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20mg/kg iv every 28 days for 3 infusions